Profesor Mark Molloy’s expertise is centred on the development and application of proteomic analyses for addressing problems in the life-sciences. His expertise in the use of mass spectrometry as the core analytical technique supports collaborative research in many science and biomedical areas, where he has a particularly strong focus towards translational cancer research. A major theme has been development of new mass spectrometry workflows for quantitative targeted proteomic analyses. This has enabled investigation of important questions such as the molecular characterisation of colon, thyroid and pancreatic cancers, melanomas and some lung cancers. The information has been used to identify prognostic and predictive protein biomarkers. More recently, he has opened a new research direction to use high resolution mass spectrometry for pharmacokinetic monitoring of cancer drug levels in cancer patients and is explore analysis from dried blood spots.

Mark’s leadership and international standing in the application of proteomics is evidenced by outstanding grant success (career total $42.9M), publications (>150), Scopus citations (>5,000) and HDR student completions (14). He was Director of the Australian Proteome Analysis Facility 2010-18 where his team provided expertise and world-class proteomic infrastructure to ~100 external academic and industry end-users each year.  

Mark completed his PhD in proteomic sciences at Macquarie University under the supervision of Keith Williams before conducting post-doctoral research at the University of Michigan Medical School in Ann Arbor, USA. He then worked in the US pharmaceutical industry at Pfizer Inc for four years. He returned to Australia to carry out a National Health and Medical Research Council career development award fellowship on colorectal cancer (CRC) biomarker proteins before becoming Director of APAF.

He is an Honorary Professor in the Department of Molecular Sciences and Professor at The University of Sydney.